BC Week In Review | Jun 2, 2014
Clinical News

Kiacta eprodisate: Completed Phase III enrollment

Auven completed enrollment of 230 patients in a double-blind, placebo-controlled, international Phase III trial of oral 400 mg Kiacta. Patients will receive 1-3 capsules of Kiacta twice daily and the dosing will be adjusted in...
BC Week In Review | May 12, 2014
Company News

Auven Therapeutics, Icahn School of Medicine at Mount Sinai deal

Mount Sinai granted private equity firm Auven Therapeutics (formerly Celtic Therapeutics) exclusive, worldwide rights to develop and commercialize Kiacta eprodisate to treat chronic sarcoidosis. Auven plans to begin a Phase II trial in 4Q14 for...
BC Week In Review | Dec 9, 2013
Clinical News

Kiacta eprodisate: Phase III ongoing

Bellus disclosed in its 3Q13 earnings that in October a DSMB recommended continuation of a double-blind, placebo-controlled, international Phase III trial of oral Kiacta in about 230 patients based on safety data. The product has...
BC Week In Review | Aug 5, 2013
Clinical News

Kiacta eprodisate regulatory update

Bellus said Japan's Ministry of Health, Labor and Welfare (MHLW) granted Orphan Drug designation for Kiacta eprodisate to treat amyloid A (AA) amyloidosis. The small molecule inhibitor of amyloid fiber formation is in Phase III...
BC Week In Review | Apr 9, 2012
Company News

Bellus Health, Pharmascience deal

Generics company Pharmascience will pay C$17.3 million ($17.4 million) to recapitalize Bellus Health into a new public company. Pharmascience will provide C$8.2 million ($8.2 million) in non-dilutive capital to Bellus and will make a C$9.1...
BC Extra | Apr 6, 2012
Company News

Pharmascience to pay $17.4M to recapitalize Bellus

Generics company Pharmascience Inc. (Montreal, Quebec) will pay C$17.3 million ($17.4 million) to recapitalize Bellus Health Inc. (TSX:BLU) into a new public company. Pharmascience will provide C$8.2 million ($8.2 million) in non-dilutive capital to Bellus...
BC Week In Review | Apr 11, 2011
Company News

Bellus Health sales and marketing update

Bellus Health restructured and will reduce headcount by an additional 8 (44%) to 10 by the end of the quarter in order to save cash. Bellus had 34 employees in August 2010, when it began...
BC Week In Review | Dec 20, 2010
Clinical News

Kiacta eprodisate: Phase III started

Celtic Therapeutics began a double-blind, placebo-controlled, international Phase III trial to evaluate oral Kiacta in about 230 patients. Bellus granted exclusive, worldwide rights to Celtic to Kiacta (see BioCentury, May 3). Bellus Health Inc. (TSX:BLU),...
BC Week In Review | May 10, 2010
Clinical News

Eprodisate: Development discontinued

Bellus discontinued its NC-503 diabetes development program after the compound missed the primary endpoint in a Phase IIa trial to treat Type II diabetes. The compound is also in Phase III testing as Kiacta to...
BC Week In Review | May 3, 2010
Company News

Bellus Health, Celtic Therapeutics Holdings L.P. deal

Bellus granted Celtic Therapeutics exclusive, worldwide rights to Kiacta eprodisate. Celtic will fund development costs through a confirmatory Phase III trial and other development activities estimated to cost about $20 million. Celtic is responsible for...
Items per page:
1 - 10 of 108